# A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

> **NCT02326025** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 49 (actual)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Olaratumab
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT02326025
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-22
- **Primary completion:** 2015-05-20
- **Final completion:** 2018-11-02
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326025, "A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02326025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*